Kas WuXi AppTec Co dividend on kindel?
WuXi AppTec Co on suurendanud dividendi juba 3 aastat.
Viimase 10 aasta jooksul on WuXi AppTec Co seda igal aastal 0 % alandatud.
5-aastases perspektiivis tõusis dividendimakse 27,311 %.
Analaütikud prognoosivad käesolevaks majandusaastaks Dividenditõus kasvu 7,458%.
WuXi AppTec Co Aktienanalyse
Mis teeb WuXi AppTec Co?
WuXi AppTec Co Ltd is a Chinese company that was founded in 2000 and specializes in the development of customer-oriented services in the pharmaceutical research and in vitro diagnostics sectors. The company operates multiple facilities in China, the USA, Europe, and Singapore.
The business model of WuXi AppTec is based on the development and provision of services to meet the needs of customers worldwide. This includes activities such as bioanalysis, chemical development, drug manufacturing, and regulatory compliance and quality assurance services.
In terms of various industries, the company is divided into three main divisions.
The Chemical Division specializes in chemical development and drug manufacturing. The team has expertise in synthesizing complex molecules, scaling up for clinical trials, manufacturing bulk products for commercial use, and supplying APIs for formulation. The company has state-of-the-art facilities and technologies to ensure high product quality and fast production time.
The Medical Device Division provides in vitro diagnostics for the global market to enable rapid and reliable medical diagnosis. The focus is on developing innovative technologies and applications in the fields of oncology, infectious diseases, and neurology. The company has many partnerships with leading in vitro diagnostics companies to enhance the quality and reach of products and services.
The Biological Division specializes in the development of biopharmaceutical products and services. This includes the development of monoclonal antibodies to the production of recombinant proteins. The services include process development, manufacturing, characterization, and analysis of biological products. WuXi AppTec is at the forefront of technology and provides its customers with state-of-the-art facilities and technologies.
In addition to the aforementioned services, WuXi AppTec also offers solutions in the field of bioanalytics, supporting the development of analytical methods and drug validation.
The company has also recently expanded into other areas, including the acquisition of NextCODE Health, a firm specializing in genetic diagnostics and analysis tools.
The company operates internationally and collaborates with a wide range of customers in the pharmaceutical and biotech sectors. It is also part of a global network of companies focusing on therapeutic technologies, clinical trials, drug marketing, and other aspects of the pharmaceutical industry.
WuXi AppTec aims to provide its customers with high-quality products and services that are scientifically sound and effective. The company invests in research and development to provide its customers with the latest technologies and discoveries. WuXi AppTec Co on üks populaarsemaid ettevõtteid saidil Eulerpool.com.Aktsiasäästuplaanid pakuvad investoritele atraktiivset võimalust pikema aja jooksul vara koguda. Üheks peamiseks eeliseks on nn keskmise maksumuse efekt: investeerides regulaarselt kindla summa aktsiatesse või aktsiafondidesse, ostetakse automaatselt rohkem osakuid siis, kui hinnad on madalad, ja vähem, kui need on kõrged. See võib aja jooksul viia soodsama keskmise hinna per osakuni. Lisaks võimaldavad aktsiasäästuplaanid ka väikeinvestoritel pääseda ligi kallimatele aktsiatele, kuna nendega saab liituda juba väikeste summadega. Regulaarne investeerimine soodustab ka distsiplineeritud investeerimisstrateegiat ja aitab vältida emotsionaalsete otsuste, nagu impulsiivne ostmine või müümine. Peale selle saavad investorid osa aktsiate võimalikust väärtuse kasvust ning dividendide väljamaksetest, mida saab reinvesteerida, mis tugevdab intressiintressi efekti ning seeläbi investeeritud kapitali kasvu.